European Agency for the Strategic

Management Against Cancer (EASMAC)

Evidence Based Cancer Treatment, Reimbursement and Research

EASMAC plans to become a pan-european “Supraministery” fighting cancer and aiming at reducing differences between and within the EU Member States

Every year 13% of deaths have cancer as their cause [1], making cancer the leading cause of mortality in the western world [2]. Actually, in 2012 this was translated in 1.270.000 deaths due to cancer among the 28 EU member states [3]. Besides the high cancer-related mortality, other identified factors contributing to this high rate are, among others: differences amongst the countries in the way that cancer is treated [4], social [5-7] and economic [8] patient conditions, cancer research fragmentation [9], etc..


It is well-known within the medical community that neither a harmonised evidence based treatment [10-14] nor ways of following-up “survivors’” [15] exist within the European Union (EU) members, even for the most common types of cancer, unlike the USA, via the National Cancer Institute [16]. As a consequence each country and, sometimes, every hospital or doctor applies their own treatment schemes, whereas these are not necessarily based on well-documented, published scientific knowledge.


In order to achieve the above mentioned harmonisation, a central authority, such as a new EU Agency [17], with a recognised executive and legislative power, can be of paramount importance. Given the difficulties of such an endeavor [18], it is of a tremendous importance that the opinion and support of all stakeholders is sought.


This website hosts the future (?) European Agency for the Strategic Management Against Cancer (EASMAC). EASMAC’s missions are to:

a) Enhance cancer prevention,

b) Harmonise cancer diagnosis, treatment and follow-up methods, based on evidence based medicine,

c) Ensure the viability of social security systems and health insurances, by providing adequate reimbursement for cancer related medical acts described under (b),

d) Manage EU's financial support for cancer research,

e) Improve the (social, professional and economic) living conditions of "survivors" and

f) Promote international collaboration.

Reference List


[1] World Health Organization. Cancer. 2010 Oct.

[2] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011 Mar;61(2):69-90.

[3] Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013 Apr;49(6):1374-403.

[4] Trakatelli M, Siskou S, Proby C, Tiplica GS, Hinrichs B, Altsitsiadis E, et al. The patient journey: a report of skin cancer care across Europe. Br J Dermatol 2012 Aug;167 Suppl 2:43-52. 

[5] Signal V, Sarfati D, Cunningham R, Gurney J, Koea J, Ellison-Loschmann L. Indigenous inequities in the presentation and management of stomach cancer in New Zealand: a country with universal health care coverage. Gastric Cancer 2014 Aug 7.

[6] Lea CS, King A. Cancer in a 29-county area in eastern North Carolina: an opportunity to reduce health inequities. N C Med J 2014 Jul;75(4):287-90.

[7] Rondet C, Lapostolle A, Soler M, Grillo F, Parizot I, Chauvin P. Are immigrants and nationals born to immigrants at higher risk for delayed or no lifetime breast and cervical cancer screening? The results from a population-based survey in Paris metropolitan area in 2010. PLoS One 2014;9(1):e87046.

[8] Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer 2009 Jan 1;124(1):180-7.

[9] Pan European Networks. Research for the cancer agenda, interview with Ulrik Ringborg, Secretary General of European Academy of Cancer Sciences. 2014.

[10] Strong VE. The new era of gastric cancer in the East and West: have our approaches harmonized? Dig Surg 2013;30(2):130-1.

[11] Meldolesi E, van SJ, Dinapoli N, Dekker A, Damiani A, Gambacorta MA, et al. An umbrella protocol for standardized data collection (SDC) in rectal cancer: A prospective uniform naming and procedure convention to support personalized medicine. Radiother Oncol 2014 Jul;112(1):59-62.

[12] Asai N, Ohkuni Y, Kaneko N, Yamaguchi E, Kubo A. Relapsed small cell lung cancer: treatment options and latest developments. Ther Adv Med Oncol 2014 Mar;6(2):69-82.

[13] Lewis CM, Weber RS. Standardizing treatment: a crisis in cancer care. Otolaryngol Clin North Am 2013 Aug;46(4):671-9.

[14] Calabrese L, Tagliabue M, Maffini F, Massaro MA, Santoro L. From wide excision to a compartmental approach in tongue tumors: what is going on? Curr Opin Otolaryngol Head Neck Surg 2013 Apr;21(2):112-7.

[15] Skinner R, Oeffinger KC. Developing international consensus for late effects screening and guidance. Curr Opin Support Palliat Care 2013 Sep;7(3):303-8.

[16] National Institutes of Health. National Cancer Institute (NCI).


[17] European Union. Agencies and other EU bodies


[18] European People's Party - European Democrats. European Union's budget for 2008: Achievements of the EPP-ED Group. 2008.